Skip to main content
. 2019 Jun 19;9:529. doi: 10.3389/fonc.2019.00529

Figure 2.

Figure 2

Kaplan-Meier estimates of infield progression-free rate (A), and severe late toxicity-free rate (B) according to the selected patient subgroup or other patients.